<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37424520</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1931-8405</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>AIDS research and human retroviruses</Title><ISOAbbreviation>AIDS Res Hum Retroviruses</ISOAbbreviation></Journal><ArticleTitle>Characteristics of Mpox Infections in Louisiana in the 2022 Outbreak.</ArticleTitle><Pagination><StartPage>587</StartPage><EndPage>592</EndPage><MedlinePgn>587-592</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/AID.2023.0011</ELocationID><Abstract><AbstractText>The 2022 outbreak of mpox in Louisiana was limited to just &gt;300 cases, perhaps an unexpected outcome given the state's high rates of HIV and other sexually transmitted infections (STIs). We aimed to describe the local outbreak within two health centers in the New Orleans region, partnering with the Louisiana Department of Health to offer additional statewide data. We reviewed charts of persons testing positive for mpox in New Orleans from July to November 2022 at two local health centers that together accounted for half of local cases. We abstracted data on HIV status, immune function [CD4 count, viral load (VL)], antiretroviral therapy regimen, symptoms and severity of infection, vaccination status, and whether tecovirimat was administered. We present local data relative to statewide data (July 2022-January 2023). Of 103 individuals in our network for whom charts were reviewed, 96 (93%) identified as male, 52 (50%) were Black, and 69 (67%) had HIV, including 12 (17%) with uncontrolled HIV (CD4&#x2009;&lt;&#x2009;200 cells/mm<sup>3</sup> or VL &gt;200 copies/mL). The most common presenting symptoms were rash (<i>n</i>&#x2009;=&#x2009;71, 69%), fever (<i>n</i>&#x2009;=&#x2009;36, 35%), and rectal pain (<i>n</i>&#x2009;=&#x2009;33, 32%). Of six (6%) patients hospitalized, four (67%) were persons with HIV (PWH). Two were hospitalized for severe mpox infection with &gt;100 lesions at presentation; both were PWH, and one had uncontrolled infection. Across the state, 307 cases have been identified and 24 have been hospitalized. Of those hospitalized, 18 (75%) were PWH, including 9 (50%) with uncontrolled HIV. The demographic data from Louisiana, a state with high prevalence of STIs and HIV/AIDS, are consistent with prior reports describing the 2022 mpox outbreak. Our results contribute to accumulating data on the severity of infection in individuals with HIV-related immunocompromise.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Essajee</LastName><ForeName>Nabil M</ForeName><Initials>NM</Initials><Identifier Source="ORCID">0000-0003-1133-7234</Identifier><AffiliationInfo><Affiliation>Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oddo-Moise</LastName><ForeName>Hope</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagensee</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lillis</LastName><ForeName>Rebecca A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maffei</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butler</LastName><ForeName>Isolde</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>CrescentCare Federally Qualified Health Center, New Orleans, Louisiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lovett</LastName><ForeName>Aish</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sokol</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Office of Public Health, Louisiana Department of Health, New Orleans, Louisiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clement</LastName><ForeName>Meredith E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0002-0283-6368</Identifier><AffiliationInfo><Affiliation>Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 AI137121</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AIDS Res Hum Retroviruses</MedlineTA><NlmUniqueID>8709376</NlmUniqueID><ISSNLinking>0889-2229</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="Y">HIV Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045908" MajorTopicYN="Y">Mpox, Monkeypox</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012749" MajorTopicYN="Y">Sexually Transmitted Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008145" MajorTopicYN="N" Type="Geographic">Louisiana</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018791" MajorTopicYN="N">CD4 Lymphocyte Count</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HIV</Keyword><Keyword MajorTopicYN="N">immunocompromise</Keyword><Keyword MajorTopicYN="N">mpox</Keyword></KeywordList><CoiStatement>M.E.C. has received research support (grants to institution) from Gilead Sciences and Viiv Healthcare and has served on advisory boards for Viiv Healthcare. R.A.L has served as a clinical trial site PI for Cepheid, Hologic, Visby, Roche, Becton Dickenson, OrthoQuidel (formerly OrthoClinical Diagnostics), Merck, and BioFire as well as a clinical trial sub-I for Gilead. R.A.L. has served as a consultant for Roche and on the speakers' bureau for Cepheid. The other authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>10</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37424520</ArticleId><ArticleId IdType="pmc">PMC10621655</ArticleId><ArticleId IdType="doi">10.1089/AID.2023.0011</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
CDC. Mpox in the U.S. 2023. Available from: https://www.cdc.gov/poxvirus/monkeypox/response/2022/us-map.html [Last accessed: January
30, 2023].</Citation></Reference><Reference><Citation>
Mpox. 2023. Available from: https://www.ldh.la.gov/page/mpox [Last accessed: May
12, 2023].</Citation></Reference><Reference><Citation>
Mpox in the U.S.
2023. Available from: https://www.cdc.gov/poxvirus/mpox/if-sick/transmission.html [Last accessed: May
21, 2023].</Citation></Reference><Reference><Citation>Pan D, Nazareth J, Sze S, et al. . Transmission of monkeypox/mpox virus: A narrative review of environmental, viral, host, and population factors in relation to the 2022 international outbreak. J Med Virol 2023;95(2):e28534; doi: 10.1002/jmv.28534</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28534</ArticleId><ArticleId IdType="pmc">PMC10107822</ArticleId><ArticleId IdType="pubmed">36708091</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazra A, Cherabie JN. Is Mpox a sexually transmitted infection? Why narrowing the scope of this disease may be harmful. Clin Infect Dis 2023;76(8):1504&#x2013;1507; doi: 10.1093/cid/ciac962</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac962</ArticleId><ArticleId IdType="pubmed">36546644</ArticleId></ArticleIdList></Reference><Reference><Citation>Allan-Blitz L-T, Gandhi M, Adamson P, et al. . A position statement on Mpox as a sexually transmitted disease. Clin Infect Dis 2022;76(8):1508&#x2013;1512; doi: 10.1093/cid/ciac960</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac960</ArticleId><ArticleId IdType="pmc">PMC10110265</ArticleId><ArticleId IdType="pubmed">36546646</ArticleId></ArticleIdList></Reference><Reference><Citation>Saldana CS, Kelley CF, Aldred BM, et al. . Mpox and HIV: A narrative review. Curr HIV/AIDS Rep 2023;1&#x2013;9; doi: 10.1007/s11904-023-00661-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11904-023-00661-1</ArticleId><ArticleId IdType="pmc">PMC10182557</ArticleId><ArticleId IdType="pubmed">37178205</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldred B KC, Colasanti J, Marconi V, et al. . Characteristics of the 2022 Mpox outbreak in a southeastern US city. [abstract]. In: Presented at: Conference on Retroviruses and Opportunistic Infections, Seattle, Washington; 2023.</Citation></Reference><Reference><Citation>
Louisiana Health Alert Message 23-07: Increasing Numbers of Syphilis, Congenital Syphilis and Diagnoses of Other Sexually Transmitted Infections Across Louisiana. 2023. Available from: https://ldh.la.gov/assets/oph/Center-CP/HANs/2023/HANS23-07-IncreasingNumbersSyphilis-Congenital-Syphilis-Diagnoses-Sexually-Transmitted-Infections-Louisiana.pdf [Last accessed: May
21, 2023].</Citation></Reference><Reference><Citation>
Louisiana HIV, AIDS, and Early Syphilis Surveillance Quarterly Report. 2022. Available from: https://ldh.la.gov/assets/oph/HIVSTD/2022-reports/ThirdQuarter-2022-HIV-Syphilis-Report_final.pdf [Last accessed: May
21, 2023].</Citation></Reference><Reference><Citation>
Louisiana STI/HIV/Hepatitis B &amp; C Update 2021 Data Tables. 2021. Available from: https://ldh.la.gov/assets/oph/HIVSTD/Tables-Profiles/data/Louisiana_DataTables-2021_updated.pdf [Last accessed: May
21, 2023].</Citation></Reference><Reference><Citation>Miller MJ, Cash-Goldwasser S, Marx GE, et al. . Severe Monkeypox in hospitalized patients&#x2014;United States, August 10&#x2013;October 10, 2022. MMWR Morb Mortal Wkly Rep 2022;71(44):1412&#x2013;1417; doi: 10.15585/mmwr.mm7144e1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7144e1</ArticleId><ArticleId IdType="pmc">PMC9639440</ArticleId><ArticleId IdType="pubmed">36327164</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitj&#xe0; O, Alemany A, Marks M, et al. . Mpox in people with advanced HIV infection: A global case series. Lancet 2023;401(10380):939&#x2013;949; doi: 10.1016/S0140-6736(23)00273-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(23)00273-8</ArticleId><ArticleId IdType="pubmed">36828001</ArticleId></ArticleIdList></Reference><Reference><Citation>
Mpox and HIV. 2023. Available from: https://www.cdc.gov/poxvirus/mpox/prevention/hiv.html [Last accessed: June
4, 2023].</Citation></Reference><Reference><Citation>Soelaeman RH. Characteristics of JYNNEOS Vaccine Recipients Before and During a Large Multiday LGBTQIA+ Festival&#x2014;Louisiana, August 9&#x2013;September 5, 2022. MMWR Morb Mortal Wkly Rep 2022;71; doi: 10.15585/mmwr.mm7143e3</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7143e3</ArticleId><ArticleId IdType="pmc">PMC9620571</ArticleId><ArticleId IdType="pubmed">36301814</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris PA, Taylor R, Thielke R, et al. . Research electronic data capture (REDCap)&#x2014;A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42(2):377&#x2013;381; doi: 10.1016/j.jbi.2008.08.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2008.08.010</ArticleId><ArticleId IdType="pmc">PMC2700030</ArticleId><ArticleId IdType="pubmed">18929686</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris PA, Taylor R, Minor BL, et al. . The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 2019;95:103208; doi: 10.1016/j.jbi.2019.103208</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2019.103208</ArticleId><ArticleId IdType="pmc">PMC7254481</ArticleId><ArticleId IdType="pubmed">31078660</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeller M, Gangavarapu K, Anderson C, et al. . Emergence of an early SARS-CoV-2 epidemic in the United States. Cell 2021;184(19):4939&#x2013;4952.e15; doi: 10.1016/j.cell.2021.07.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.07.030</ArticleId><ArticleId IdType="pmc">PMC8313480</ArticleId><ArticleId IdType="pubmed">34508652</ArticleId></ArticleIdList></Reference><Reference><Citation>Kava CM. Epidemiologic features of the Monkeypox outbreak and the public health response&#x2014;United States, May 17&#x2013;October 6, 2022. MMWR Morb Mortal Wkly Rep 2022;71; doi: 10.15585/mmwr.mm7145a4</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7145a4</ArticleId><ArticleId IdType="pmc">PMC9707350</ArticleId><ArticleId IdType="pubmed">36355615</ArticleId></ArticleIdList></Reference><Reference><Citation>
Health Alert Network (HAN)&#x2014;00490 | Potential Risk for New Mpox Cases. 2023. Available from: https://www.emergency.cdc.gov/han/2023/han00490.asp [Last accessed: May
21, 2023].</Citation></Reference><Reference><Citation>
2022 U.S. Map &amp; Case Count | Mpox | Poxvirus | CDC. 2023. Available from: https://www.cdc.gov/poxvirus/mpox/response/2022/us-map.html [Last accessed: June
7, 2023].</Citation></Reference><Reference><Citation>Payne AB. Reduced risk for Mpox after receipt of 1 or 2 doses of JYNNEOS vaccine compared with risk among unvaccinated persons&#x2014;43 U.S. Jurisdictions, July 31&#x2013;October 1, 2022. MMWR Morb Mortal Wkly Rep 2022;71; doi: 10.15585/mmwr.mm7149a5</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7149a5</ArticleId><ArticleId IdType="pmc">PMC9762900</ArticleId><ArticleId IdType="pubmed">36480479</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrar JL, Lewis NM, Houck K, et al. . Demographic and clinical characteristics of Mpox in persons who had previously received 1 dose of JYNNEOS vaccine and in unvaccinated persons&#x2014;29 U.S. Jurisdictions, May 22&#x2013;September 3, 2022. MMWR Morb Mortal Wkly Rep 2022;71(5152):1610&#x2013;1615; doi: 10.15585/mmwr.mm715152a2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm715152a2</ArticleId><ArticleId IdType="pmc">PMC9812445</ArticleId><ArticleId IdType="pubmed">36580416</ArticleId></ArticleIdList></Reference><Reference><Citation>
Mpox in the U.S.
2022. Available from: https://www.cdc.gov/poxvirus/mpox/response/2022/amis-select-behaviors.html [Last accessed: May
23, 2023].</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>